A new guideline for anemia in chronic kidney disease (CKD) emphasizes individualized care and emerging therapies. The guideline's release has prompted discussion of various treatments, including novel iron therapies and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Research on these and other therapies, such as vadadustat, is ongoing, with some studies examining their effectiveness and potential risks.